About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson’s diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson’s program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren’s syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company’s proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York. Address: 430 East 29th Street, New York, NY, United States, 10016
MeiraGTx Holdings plc News and around…
Latest news about MeiraGTx Holdings plc (MGTX) common stock and company :
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Amgen Inc (AMGN), where a total of 23,460 contracts have traded so far, representing approximately 2.3 million underlying shares. That amounts to about 68.5% of AMGN's average daily trading volume over the past month of 3.4 million shares..
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $167.60 per unit.
MeiraGTx Hldgs (NASDAQ:MGTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what ...
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients- Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induced Xerostomia Completed Dosing of Both Unilateral and Bilateral Cohorts in the First Quarter of 2022 LONDON and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results fo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of -3.03% and 16.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LONDON and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis Pigmentosa (XLRP) were presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting (ARVO), in Denver, Colorado by Professor Michel Michaelides. A poster presentation of human r
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 16.52% and 2.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio’s President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment
LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor and scientific conferences: Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Corporate Presentation: Monday, April 25, 2022, at 10:30 a.m. ET Panel Discussion: – “Evolving standards of AAV
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $89.78 per unit.
MeiraGTx Holdings plc ( NASDAQ:MGTX ) shareholders will have a reason to smile today, with the analysts making...
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 55.10% and 202.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enrolling and Dosing Patients- Received $30 Million Cash Milestone Payment from Janssen Pharmaceuticals, Inc.- Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Radiation-Induced Xerostomia Announced- First In Vivo Data from Riboswitch Gene Regulation Platform at R&D Day Presented LONDON and NEW YORK, March 10, 2022 (GLO
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
If you want to know who really controls MeiraGTx Holdings plc ( NASDAQ:MGTX ), then you'll have to look at the makeup...
Bluebird (BLUE) delivered earnings and revenue surprises of 0% and 79.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in nLight Inc (LASR), where a total volume of 1,171 contracts has been traded thus far today, a contract volume which is representative of approximately 117,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 44.1% of LASR's average daily trading volume over the past month, of 265,360 shares..
-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the Phase 3 Lumeos Clinical Trial in X-linked Retinitis Pigmentosa -MeiraGTx Remains Eligible for Further Development and Commercial Milestones Related to botaretigene sparoparvovec (AAV-RPGR), as well as for AAV-CNGB3 and AAV-CNGA3 LONDON and NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinic
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and conference call on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ET highlighting the Company’s gene regulation platforms. MeiraGTx’s R&D Day webcast will feature a presentation by Alexandria Forbes, Ph.D., President and Chief Executive Officer. The event will provide a detailed overview
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million ...
MeiraGTx Holdings plc(NASDAQ: MGTX) hasannounced preliminary datafrom the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive ...
Clinically meaningful improvements in xerostomia symptoms and disease burden reported in two validated Patient Reported Outcome (PRO) measures6 of the 7 participants through 90-day assessments following treatment achieved clinically meaningful improvement in symptoms using both the McMaster Global Rate of Change PRO and the Xerostomia QuestionnaireOne participant with the maximum response evaluable at 12 months has now reached 24 months and the same level of response/xerostomia symptom improveme
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt ...
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
MeiraGTx Holdings plc (MGTX) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
